ADISO PORTFOLIO



Multimodal activity contributes to efficacy while local targeting diminishes risk of off-target effects including immunosuppression
Our Pipeline
Small Molecule Modulator of Neutrophil Trafficking and Activation
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
ADS051
First-In-Class Small Molecule Inhibitor of the NLRP1 and 3 Inflammasomes
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
ADS032
Single Strain Live Biotherapeutic Product (SS-LBP) Platform
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
ADS024 CDI
ADS024 UC
ADS00X